Skip to content
Beacon

BISProShares UltraShort Nasdaq Biotechnology

Take a bet16y track recordRanked #549 of 775 in this goal

Seeks daily investment results of -200% of the daily performance of the Nasdaq Biotechnology Index.

By ProShares · Launched 2010

Annual Cost

0.95%

#4,684 of 5,562 · expensive

Fund Size

$2M

#5,289 of 5,562 · small

Return (1Y)Goal

-53.0%

Track Record

16 years

#768 of 5,562 · established

Performance

Total-return NAV · USD
Growth of $10,000
$4,247-57.5%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Strategy

Inverse

Sector

Health care

Index tracked

Nasdaq Biotechnology Index

What it actually holds

By weight

Concentration

Top 10 holdings = 108.4% of fundconcentrated

Repurchase Agreement
33.3%
Repurchase Agreement
23.2%
Repurchase Agreement
20.1%
Repurchase Agreement
8.1%
Repurchase Agreement
8.1%
Repurchase Agreement
6.0%
Repurchase Agreement
6.0%
Repurchase Agreement
3.9%
Repurchase Agreement
2.0%
N/A
-2.3%

Asset allocation

Cash
199.9%
Other
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
40.4%High

Year-on-year price swings

Max drawdown
-95.2%Severe

Worst peak-to-trough loss

Sharpe (3Y)
-0.53Below average
Sortino (3Y)
-0.74Moderate downside risk

Where to buy

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks daily investment results of -200% of the daily performance of the Nasdaq Biotechnology Index.
Strategy
Invests primarily in financial instruments to achieve inverse leveraged exposure to the Nasdaq Biotechnology Index. The Fund rebalances daily to maintain its target exposure, using derivatives and other instruments related to biotechnology and pharmaceutical companies.
Inception date
April 6, 2010
Fund family
ProShares

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Inverse
Warning

Inverse ETF — daily tool only

Delivers the inverse of the benchmark's daily return. The compounding path makes multi-day holding unpredictable even when the benchmark's total move goes your way. Legitimate as a one-day hedge; dangerous as a view.

Source: Cheng & Madhavan (2009)

Why we flagged this: strategy=inverse + inverse_name_or_strategy

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've reviewed BIS. Save it to your watchlist to track it alongside the other funds you're weighing.

Data updated on 2026-06-20